Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

990.33 +7.07 (+0.72%)

Official Closing Price Updated: 7:00 PM EST, Mar 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Nvidia's 2 Surprises; NVDA Soars On Trump-Fueled Hopes of China Blackwell Sales; Fed In Focus ↗

October 29, 2025

Two Nvidia Shockers Please click here for an enlarged chart of NVIDIA Corp (NASDAQ:NVDA).

Via Benzinga

Topics Economy

Earnings Outlook For Eli Lilly ↗

October 29, 2025

Via Benzinga

Nvidia's AI Reign: Fueling Market Gains and Forging a New Industrial Revolution

October 29, 2025

Nvidia (NASDAQ: NVDA) stands as the undisputed titan of the artificial intelligence (AI) era, its stock performance a primary catalyst for the recent, unprecedented surge in global financial markets....

Via MarketMinute

Topics Artificial Intelligence Economy Government

Eli Lilly To Acquire Adverum Biotechnologies ↗

October 24, 2025

Via Stocktwits

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

October 29, 2025

Via Investor Brand Network

Eli Lilly Partners With Walmart To Expand Access To Popular Weight-loss Drug ↗

October 29, 2025

Zepbound vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November.

Via Stocktwits

1 Incredible Reason to Buy Novo Nordisk Stock (NVO) in November -- or Sooner ↗

October 29, 2025

It offers compelling weight-loss drugs -- and a compelling stock price, too.

Via The Motley Fool

Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? ↗

October 29, 2025

This stock has caught fire after some recent events, but how long will that last?

Via The Motley Fool

Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability

October 29, 2025

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END

Via FinancialNewsMedia

Eli Lilly (LLY) To Report Earnings Tomorrow: Here Is What To Expect

October 28, 2025

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be announcing earnings results this Thursday before market open. Here’s what investors should know.

Via StockStory

1 Undervalued Growth Stock Down 8% to Buy Before 2026 ↗

October 28, 2025

This momentary pullback represents an excellent opportunity to buy this high-flying stock.

Via The Motley Fool

Topics World Trade

Eli Lilly Partners With Nvidia To Build Pharma’s Most Powerful AI Supercomputer ↗

October 28, 2025

The Nvidia-powered system aims to cut drug development times and boost innovation.

Via Talk Markets

Topics Artificial Intelligence

Why Nvidia (NVDA) Stock Is Up Today

October 28, 2025

Shares of leading designer of graphics chips Nvidia (NASDAQ:NVDA) jumped 5.2% in the afternoon session after CEO Jensen Huang laid out an overwhelmingly bullish case for the company's future at a...

Via StockStory

Topics Artificial Intelligence Government World Trade

Ken Paxton Alleges Johnson & Johnson Misled Mothers On Tylenol Safety ↗

October 28, 2025

Texas Attorney General Ken Paxton sued Johnson & Johnson and Kenvue, alleging Tylenol was deceptively marketed as safe for pregnant women.

Via Benzinga

Topics Lawsuit

Why NeoGenomics (NEO) Stock Is Trading Up Today

October 28, 2025

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 1.1% in the morning session after it reported third-quarter 2025 results where revenue beat Wall Street's expectations.

Via StockStory

Topics World Trade

If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These ↗

October 28, 2025

These two have been neglected by Wall Street too much.

Via The Motley Fool

Eli Lilly & Co (NYSE:LLY) Presents a High Growth Momentum and Technical Breakout Opportunity ↗

October 28, 2025

Eli Lilly (LLY) is a top growth momentum stock with accelerating earnings, strong technical ratings, and a positive breakout setup for investors.

Via Chartmill

Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers

October 27, 2025

As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Peering Into Eli Lilly and Co's Recent Short Interest ↗

October 27, 2025

Via Benzinga

BDF-GESTION Trims Its Eli Lilly (LLY) Stake by 4,149 Shares ↗

October 27, 2025

BDF-GESTION Trims Its Eli Lilly (LLY) Stake by 4,149 Shares

Via The Motley Fool

What Is 1 of the Best Pharmaceutical Stocks to Buy Now? ↗

October 27, 2025

This pharma giant is entering the rapidly expanding market for weight loss drugs.

Via The Motley Fool

Down 15%, Should You Buy the Dip on Eli Lilly? ↗

October 27, 2025

Lilly's stock has pulled back from its 2024 highs, but that doesn't mean the shares are cheap enough to buy.

Via The Motley Fool

Topics Intellectual Property

Viking Therapeutics: High Risk, High Reward Play ↗

October 27, 2025

Via MarketBeat

Should You Buy Eli Lilly Stock Before Oct. 30? ↗

October 27, 2025

Long-term investors don't need to rush to buy Eli Lilly stock.

Via The Motley Fool

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal ↗

October 27, 2025

Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash.

Via Benzinga

BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? ↗

October 26, 2025

The clinical-stage biotech is working on a new type of weight management drug.

Via The Motley Fool

Eli Lilly And Co. Stock: Gains As $12.47-Per-Share Adverum Biotech Deal Expands Gene Therapy Portfolio ↗

October 24, 2025

Eli Lilly stock rises as $12.47-per-share Adverum Biotech deal boosts its gene therapy ambitions and expands ophthalmology pipeline.

Via Talk Markets

Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis ↗

October 24, 2025

Eli Lilly reports new data showing sustained efficacy for Ebglyss with less frequent dosing and strong long-term results for Olumiant in hair regrowth.

Via Benzinga

Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections ↗

October 24, 2025

Lilly (LLY) to acquire Adverum Biotechnologies (ADVM) for $12.47 per share, with potential CVR payments tied to future milestones.

Via Benzinga

Eli Lilly Options Trading: A Deep Dive into Market Sentiment ↗

October 24, 2025

Via Benzinga

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.